Form 4: Gossamer Bio Reprices Executive Stock Options to $0.45

Gossamer Bio, Inc. has repriced nearly 2 million outstanding stock options for EVP Caryn Peterson to an exercise price of $0.45 per share, effective March 19, 2026.

Summary

• Gossamer Bio, Inc. (GOSS) approved a one-time repricing of certain outstanding stock options for Caryn Peterson, Executive Vice President of Regulatory Affairs.
• The repricing reduced the per share exercise price of 1,992,753 stock options to $0.45, effective March 19, 2026.
• These options were originally granted under the Issuer's 2019 Incentive Award Plan with exercise prices ranging from $0.838 to $2.88.
• All other terms and conditions of the repriced options, including vesting schedules and term, remain unchanged.
• The options become exercisable in accordance with their original vesting schedules, contingent on Ms. Peterson's continued service with the Issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed signal. While it re-incentivizes a key executive, the repricing of underwater options can be perceived negatively by shareholders regarding corporate governance and past stock performance.

Positives

• The repricing significantly lowers the exercise price for 1,992,753 stock options held by EVP Caryn Peterson, potentially increasing their intrinsic value and providing renewed incentive.
• The new exercise price of $0.45 is substantially below the original exercise prices, which ranged from $0.838 to $2.88, making the options more likely to be in-the-money.

Negatives

• Option repricing can be viewed negatively by shareholders as it effectively provides a 'do-over' for underwater options, potentially signaling past underperformance or a lack of confidence in future stock price appreciation at higher levels.
• While not immediately dilutive, the repricing makes it more likely that these options will be exercised, leading to potential future dilution for existing shareholders.

Risks

• Repricing options can raise corporate governance concerns among investors, who may perceive it as a management-friendly action that does not align with shareholder interests if the original options were underwater due to poor company performance.
• The action could be interpreted as a lack of confidence by the board that the stock price will recover sufficiently to make the original, higher-priced options valuable, potentially impacting investor sentiment.

Future Outlook

The repricing of stock options is intended to re-incentivize the executive by making the options more valuable, potentially aligning their interests more closely with future stock price appreciation from the new, lower base.

Management Comments

• The Issuer approved a one-time repricing of certain outstanding stock options granted under the 2019 Incentive Award Plan.
• Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

Industry Context

StockSavvy.ai notes that option repricing typically occurs when a company's stock price has fallen significantly, rendering previously granted options 'underwater' and thus less effective as an incentive. While common in certain market conditions, particularly in biotech where stock volatility can be high, it often draws scrutiny from institutional investors and proxy advisory firms regarding its impact on shareholder value and executive accountability.

Comparison to Industry Standards

• Option repricing is a practice that has seen varying levels of acceptance across industries. In the biotechnology sector, where Gossamer Bio operates, stock prices can be highly volatile due to clinical trial results and regulatory milestones, often leading to options becoming underwater.
• Compared to broader market benchmarks, repricing is generally less common among large-cap, stable companies but more prevalent in growth-oriented or early-stage companies facing significant stock price declines.
• Companies like Zynerba Pharmaceuticals (ZYNE) and Aerie Pharmaceuticals (AERI) have also undertaken option repricings in the past when their stock prices significantly underperformed, aiming to restore incentive value for key personnel. The specific terms, such as the magnitude of the price reduction and the number of options involved, are critical for comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if the repriced options are exercised, and possible concerns regarding corporate governance and the board's approach to executive incentives following stock price declines.
• Executive (Caryn Peterson): Significantly increased potential value of her stock options, providing renewed financial incentive and retention.

Next Steps

• The repriced stock options will continue to vest according to their original schedules, subject to Caryn Peterson's continued employment with Gossamer Bio, Inc.

Key Dates

Keywords

Gossamer Bio, GOSS, stock options, option repricing, executive compensation, Form 4, insider transaction, equity incentive plan, corporate governance